Practical Effect of Sorafenib Monotherapy on Advanced Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis.
- Author:
Soung Won JEONG
1
;
Jae Young JANG
;
Kwang Yeun SHIM
;
Sae Hwan LEE
;
Sang Gyune KIM
;
Sang Woo CHA
;
Young Seok KIM
;
Young Deok CHO
;
Hong Soo KIM
;
Boo Sung KIM
;
Kyoung Ha KIM
;
Jung Hoon KIM
Author Information
1. Division of Gastroenterology, Department of Internal Medicine, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Seoul, Korea. jyjang@schmc.ac.kr
- Publication Type:Original Article ; Clinical Trial
- Keywords:
Carcinoma, hepatocellular;
Portal vein;
Thrombosis;
Sorafenib
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Anorexia/chemically induced;
Antineoplastic Agents/adverse effects/*therapeutic use;
Carcinoma, Hepatocellular/*drug therapy/pathology;
Diarrhea/chemically induced;
Disease-Free Survival;
Fatigue/chemically induced;
Female;
Hand-Foot Syndrome/etiology;
Humans;
Kaplan-Meier Estimate;
Liver Neoplasms/*drug therapy/pathology;
Magnetic Resonance Imaging;
Male;
Middle Aged;
Nausea/chemically induced;
Neoplasm Invasiveness;
Niacinamide/adverse effects/*analogs & derivatives/therapeutic use;
Phenylurea Compounds/adverse effects/*therapeutic use;
Portal Vein/*pathology;
Proportional Hazards Models;
Tomography, Spiral Computed;
Venous Thrombosis/*drug therapy/pathology
- From:Gut and Liver
2013;7(6):696-703
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: We investigated the effects of sorafenib monotherapy on advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) in a clinical setting. METHODS: In total, 143 consecutive patients with unresectable HCC were treated with sorafenib. Among these patients, 30 patients with advanced HCC and PVTT (Vp3 or 4) were treated with sorafenib monotherapy. RESULTS: All patients had a performance status of 1 to 2 (Eastern Cooperative Oncology Group 1/2, 20/10) and Child-Pugh class A or B (A/B, 17/13). Eleven patients had modified Union for International Cancer Control stage IVA tumors, whereas 19 had stage IVB tumors. All patients had PVTT (Vp3, 6; Vp4, 24). Following sorafenib monotherapy, three patients (10.0%) had a partial response with PVTT revascularization, and nine (30.0%) had stable disease, with a disease control rate of 33.3%. The median overall survival was 3.1 months (95% confidence interval [CI], 2.70 to 3.50), and the median progression-free survival was 2.0 months (95% CI, 1.96 to 2.05). Fatigue and hand-foot skin reactions were the most troublesome side effects. CONCLUSIONS: A limited proportion of patients with advanced HCC and PVTT exhibited a remarkable outcome after sorafenib monotherapy, although the treatment results in this type of patient is extremely poor. Further studies to predict good responders to personalized therapy are warranted.
